Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
Ferroportin mutation in autosomal dominant hemochromatosis: loss of function, gain in understanding
Robert E. Fleming, William S. Sly
Robert E. Fleming, William S. Sly
Published August 15, 2001
Citation Information: J Clin Invest. 2001;108(4):521-522. https://doi.org/10.1172/JCI13739.
View: Text | PDF
Commentary

Ferroportin mutation in autosomal dominant hemochromatosis: loss of function, gain in understanding

  • Text
  • PDF
Abstract

Authors

Robert E. Fleming, William S. Sly

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Ferroportin1 in absorption of dietary iron (a) and release of iron store...
Ferroportin1 in absorption of dietary iron (a) and release of iron stores (b). (a) Dietary nonheme iron at the luminal surface of the villus enterocyte is reduced by ferric reductase and taken up by DMT1. The iron may be retained, or transported across the basolateral surface by ferroportin1 (blue oval), oxidized by hephaestin, and bound to transferrin (Tf) for plasma transport. (b) Transferrin-bound iron (Tf-Fe) is taken up by the RE cell by a complex containing β2-microglobulin (β2M), the transferrin receptor (TfR), and the HFE protein (teal oval), which is defective in the classic, autosomal recessive form of hemochromatosis. Heme iron taken up by phagocytosis of senescent erythrocytes (RBC) is released by heme oxygenase (H.O.). The iron may be stored as ferritin, or exported via ferroportin1, after which it is oxidized by ceruloplasmin (Cp), and bound to transferrin for plasma transport. Hephaestin and ceruloplasmin, both indicated by green circles, are structurally similar and perform analogous functions, but their patterns of expression are distinct. Two recent papers, including one in this issue of the JCI, have implicated ferroportin in an atypical, autosomal dominant form of hemochromatosis (6, 7).
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts